Transmission parameter |
β
|
.3 |
.05–.5 |
[16] |
Vaccine efficacy (initial) |
e
|
.95 |
.8–1 |
[15, 16, 23, 24] |
Reduction in risk of infection for vaccinated (and protected) individuals |
e
p
|
1 |
.5–1 |
[25] |
Duration of protection from vaccination |
1/ω1
|
19.2 years |
5–25 years |
[16, 24] |
Fraction symptomatic |
σ
|
.2 |
.1–1 |
[16] |
Fraction symptomatic for vaccinated individuals |
σ
V
|
.05 |
0–.2 |
[15, 23, 25]} |
Fraction treated |
τ
|
.75 |
0–1 |
[16, 26] |
Duration of infectiousness with treatment |
1/Υ
|
1 week |
.5–3 weeks |
[19] |
Rate of treatment-induced/acquired resistance |
ρ
|
.1 per week |
.01–2 per week |
Assumption |
Natural recovery rate from first, antimicrobial-resistant infection |
δ
1,R
|
.2 per week |
.1–.5 per week |
[19] |
Relative infectiousness of resistant strain(s) |
r
R
|
.9 |
.5–2 |
Assumption, [27] |
Relative infectiousness of chronic carriers |
r
C
|
.35 |
.1–1 |
[16] |
Fraction that become carriers from first, antimicrobial-sensitive infection |
θ
1,S
|
.03 |
.003–.1 |
[28] |
Fraction that become carriers from first, antimicrobial-resistant infection |
θ
1,R
|
.03 |
.003–.1 |
[28] |
Relative rate of recovery from second infection |
δ
2,S/δ1,S = δ2,R/δ1,R
|
1 |
.5–2 |
Assumption |